Search Results 361-370 of 17485 for Vitiligo

1. A Study to Assess the Effectiveness and Safety of Durvalumab Alone or Combined with Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment - Mayo Clinic

   Participation eligibility · Patients with vitiligo or alopecia; · Patients with hypothyroidism (e.g., following Hashimoto syndrome), stable on hormone replacement ...

2. Publications - Nessa Aghazadeh Mohandesi, M.D. - Mayo Clinic

   The Effect of Expressive Writing on Psychological Distress in Patients with Vitiligo: A Randomized Clinical Trial Journal of Client-Centered Nursing Care.

3. Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer - Mayo Clinic

   Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone ...

4. Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma - Mayo Clinic

   Vitiligo;; Hemolytic anemia associated with the lymphoma (history of or at the present time);; Type I diabetes mellitus;; Residual hypothyroidism due to ...

5. An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer - Mayo Clinic

   Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not ...

6. A Study of RP2 with Nivolumab compared to Ipilimumab with Nivolumab with Metastatic Uveal Melanoma - Mayo Clinic

   ... vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or prior autoimmune conditions not expected to recur are eligible. History of ...

7. A Study of AP160-Complex in Advanced Solid Tumors - Mayo Clinic

   Vitiligo or resolved childhood asthma/atopy;; Intermittent use of bronchodilators or local steroid injections;; Non-immunosuppressive maintenance treatments ...

8. Neoadjuvant dual checkpoint blockade with PD1 and LAG-3 inhibition in resectable Non-small cell lung Cancer - Mayo Clinic

   EXCEPTIONS: patients with vitiligo; resolved childhood asthma/atopy; residual hypothyroidism that requires only hormone replacement; or psoriasis not ...

9. Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer - Mayo Clinic

   Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic ...

10. https://www.mayoclinic.org/spanish_organization_concepts.xml